Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir

Completed

• Conditions: Chronic Hepatitis C

• Registration Number: NCT01577069
• Lead Sponsor: Association HGE CHU Bordeaux Sud

Brief Summary

The purpose of the study is to

1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after Telaprevir treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-02
• Study First Submitted: 2012-04-12
• Study First Submitted QC: 2012-04-12
• Study First Posted: 2012-04-13
• Primary Completion: 2013-01
• Study Completion: 2013-01
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-21
• Last Update Posted: 2016-06-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 73

Inclusion Criteria

• HCV mono-infected subjects
• Age > 18 years

Exclusion Criteria

• HBV co-infection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
virological resitance	12 weeks after treatment

Trial Locations

Locations (1)

Hôpital du haut-Lévêque; 🇫🇷 Pessac, France